Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 30, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Sezary SyndromeMycosis Fungoides
Interventions
DRUG

Mogamulizumab

Administered 1 mg/kg as an intravenous infusion over at least 60 minutes on Days 1, 8, 15, and 22 of the first 28 day cycle and on Days 1 and 15 of each subsequent cycle.

RADIATION

LD TSEBT

Patients will receive total skin dose of 12 Gy fractionated at 4 to 6 Gy per week, for 2-3 weeks

Trial Locations (1)

94304

RECRUITING

Stanford Cancer Center, Stanford

All Listed Sponsors
lead

Stanford University

OTHER